Use of Guideline-Recommended Therapies for Heart Failure in the Medicare Population
Article first published online: 13 JUL 2010
Copyright © 2010 Wiley Periodicals, Inc.
Volume 33, Issue 7, pages 400–405, July 2010
How to Cite
DiMartino, L. D., Shea, A. M., Hernandez, A. F. and Curtis, L. H. (2010), Use of Guideline-Recommended Therapies for Heart Failure in the Medicare Population. Clin Cardiol, 33: 400–405. doi: 10.1002/clc.20760
- Issue published online: 13 JUL 2010
- Article first published online: 13 JUL 2010
- Manuscript Accepted: 13 FEB 2010
- Manuscript Received: 5 FEB 2010
Most information about the use of guideline-recommended therapies for heart failure reflects what occurred at discharge after an inpatient stay.
Using a nationally representative, community-dwelling sample of elderly Medicare beneficiaries, we examined how the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and β-blockers has changed and factors associated with their use.
Using data from the Medicare Current Beneficiary Survey cost and use files matched with Medicare claims data, we identified beneficiaries for whom a diagnosis of heart failure was reported between January 1, 2000, and December 31, 2004. Data on medications prescribed during the year of cohort entry were based on patient self-report. We used multivariable logistic regression to explore relationships between the use of ACE inhibitors/ARBs and β-blockers and patient demographic characteristics.
From 2000 through 2004, the use of ARBs increased from 12% to 19%, and the use of β-blockers increased from 30% to 41%. The use of ACE inhibitors remained constant at 45%. Beneficiaries who reported having prescription drug insurance coverage were 32% more likely than other beneficiaries to have filled a prescription for an ACE inhibitor or ARB and 26% more likely to have filled a prescription for a β-blocker.
Although the use of guideline-recommended therapies for heart failure has increased, it remains suboptimal. Copyright © 2010 Wiley Periodicals, Inc.